Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 252

Sort by

Sort Order Select

Journal Articles

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Beth M. Faiman, Louis S Williams, Jack Khouri, Faiz Anwer, Shahzad Raza, Christy J. Samaras, Kimberly Hamilton, Cynthia Scott, Saveta Mathur, Omer N. Koc, Willem J. van Heeckeren, Jason Valent, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 5170.8.

https://doi.org/10.1182/blood-2024-212088

Published: 2024

Journal Articles

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Fathima Shehnaz Ayoobkhan, Raabia Qureshi, Raeef L Rahman, Zohaa Faiz, Sohaib Irfan, Ahmad Iftikhar, Briha Ansari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Shahzad Raza, Hira Shaikh, Forat Lutfi, Shebli Atrash, Joseph P. McGuirk, Hamza Hashmi, Faiz Anwer, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2024-208307

Published: 2024

Journal Articles

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Fathima Shehnaz Ayoobkhan, Sara Shatnawi, Moazzam Shahzad, Aqeeb Ur Rehman, Sohaib Irfan, Raabia Qureshi, Arooq Khalid, Sibgha Gull Chaudhary, Faiz Anwer, Briha Ansari, Joseph P. McGuirk, Mohamad Mohty, Nausheen Ahmed, Al-Ola Abdallah, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 5045.

https://doi.org/10.1182/blood-2024-203904

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

Disparities in Time to First Prescription Fill for Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma

Hamlet Gasoyan, Faiz Anwer, Jeffrey D. Kovach, Nicholas J Casacchia, Ming Wang, Jason Valent, Michael B. Rothberg

Blood (2024) 144 (Supplement 1): 5032.

https://doi.org/10.1182/blood-2024-201654

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Superior Safety and Efficacy of Doacs over Warfarin in Obese Patients: A Propensity-Matched Cohort Study

Usman Ali Akbar, Umer Rizwan, Ahmed Muaaz Umer, Ayesha Akbar, Michael Cheshire, Neeharika Muddana, Faiz Anwer

Blood (2024) 144 (Supplement 1): 1252.

https://doi.org/10.1182/blood-2024-202466

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Journal Articles

Clinical Outcomes and Disease Progression after Daratumumab-Based Treatment in Primary Amyloidosis

Omer Ashruf, Ali Mushtaq, Faiza Zakaria, Razwana Khanam, Faiz Anwer

Blood (2024) 144 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2024-211663

Published: 2024

Journal Articles

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Blood (2024) 144 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2024-206357

Published: 2024

Journal Articles

Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

John Hanna, Ryan Brown, Zain Ali Burney, Kawther Abdallah, Jason Valent, Christy J. Samaras, Faiz Anwer, Jack Khouri, Louis Williams, Shahzad Raza, Willem Van Heeckeren, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2024-208479

Published: 2024

Journal Articles

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Louis Williams, Danai Dima, Hanny Sawaf, Ali Mehdi, Daniel Cancilla, Hira Shaikh, Faiz Anwer, Sandra Mazzoni, Beth M. Faiman, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza

Blood (2024) 144 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2024-210799

Published: 2024

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma - a Meta-Analysis

Ahmad Iftikhar, Hiba Arshad Shahani, Mohammad Ebad Ur Rehman, Muhammad Sheraz Hameed, Syed Ali Raza Abidi, Fathima Shehnaz Ayoobkhan, Rana Uzair Ahmad, Afreen Quadri, Muhammad Suhaib, Omar A Safdar, Faiz Anwer, Muhammad Husnain

Blood (2024) 144 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2024-209502

Published: 2024

Journal Articles

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040

Rupayan Kundu, Niladri Kal, Abhay Singh, Louis Williams, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza, Willem Van Heeckeren, Faiz Anwer, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2024-211861

Published: 2024

Journal Articles

Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab

Michael Sheu, Ali Mushtaq, Sofia Molina Garcia, Faiz Anwer, Meera Patel, Thomas Andrew Crilley, Muhammad Anns Asif, Aneela Majeed

Blood (2024) 144 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2024-194386

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson, Shaun DeJarnette, Fauzia Ullah, Evguenia Ouchveridze, Mariam Markouli, Claire Yun Kyoung Ryu Tiger, Louis Williams, Sandra Mazzoni, Beth M. Faiman, Craig Sauter, Faiz Anwer, Shahzad Raza, Leyla O. Shune, Jack Khouri

Blood (2024) 144 (Supplement 1): 4708.

https://doi.org/10.1182/blood-2024-203984

Published: 2024

Journal Articles

Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma

Rabia Iqbal, Ahmad Taimoor Bajwa, Aemen Shafqat Bazaz, Mrunanjali Gaddam, Fiqe Khan, Nyan Linn Htet, Aqsa Mumtaz, Faiz Anwer

Blood (2024) 144 (Supplement 1): 4706.

https://doi.org/10.1182/blood-2024-209428

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) for Chimeric Antigen Receptor T-Cell Therapy (CAR-T) and T-Cell Engager Antibody (TCE) in Myeloma and Lymphoma

Oncologists' Perspectives and Practices on Minimal Residual Disease Testing in Multiple Myeloma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Disparities in Time to First Prescription Fill for Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Superior Safety and Efficacy of Doacs over Warfarin in Obese Patients: A Propensity-Matched Cohort Study

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Clinical Outcomes and Disease Progression after Daratumumab-Based Treatment in Primary Amyloidosis

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory Multiple Myeloma - a Meta-Analysis

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040

Infectious Risk in Multiple Myeloma Patients Undergoing Treatment with Teclistamab

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Impact of Kidney Transplantation on Hospitalization Outcomes in Patients with Multiple Myeloma

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only